The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Ludvig Svensson, Penser Access by Carnegie, Tel: +46 8 463 80 00. Penser Access by Carnegie

  Quarterly Report 3 23/24, June 26, 2024
The recent share issue, including warrants, has strengthened our financial position at this pivotal time. This capital infusion supports our efforts in advancing clinical programs and scaling operations. Importantly, this was achieved with minimal dilution for existing shareholders and at a cost substantially below prevailing market rates. With the cash position end of May of approximately 162 MSEK and a warrant structure including warrants in...
The upcoming interim analysis is a significant milestone. It will provide insights into the progression of DIAGNODE-3, specifically informing whether the trial is still on track to reach its key endpoints.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
September 9 − September 13, 2024
EASD 2024
October 9, 2024
Year-End Report
Year-End Report 2023/2024
October 16 − October 19, 2024
ISPAD 2024
November 4 − November 8, 2024
IDS 2024
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of March 28, 2024

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 12 257 304 12.91 10.25
Lindkvist, Bertil 8 700 000 9.16 7.27
Nordnet Pension 4 902 383 5.16 4.10
Essen-Möller, Anders * 741 630 3 017 040 3.96 8.72
Essen-Möller, Maria-Teresa 400 000 963 998 1.44 4.15
Konstruktions o Försäljningsaktiebolag 906 250 0.95 0.76
Essen-Möller, Jon 400 000 287 015 0.72 3.58
Esssen-Möller, Martin 400 000 306 440 0.74 3.60
Hillborg, Erika 400 000 190 000 0.62 3.50
Essenshaw, My 400 000 181 002 0.61 3.50
Remaining shareholders 60 494 934 63.71 50.57
Total 2 741 630 92 206 366 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS